德康医疗(DXCM)
icon
搜索文档
DXCM FRAUD UPDATE: A Class Action Lawsuit has been Filed Against DexCom, Inc. for Securities Fraud; Contact BFA Law Before Approaching October 21 Case Deadline (Nasdaq:DXCM)
GlobeNewswire News Room· 2024-08-28 20:17
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and ...
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against DexCom, Inc. (DXCM)
GlobeNewswire News Room· 2024-08-28 05:06
LOS ANGELES, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 21, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) securities between January 8, 2024 to July 25, 2024, inclusive (the “Class Period”). If you suffered a loss on your DexCom investments or would like to inquire about potentially pursuing claims t ...
DexCom Stock May Gain on Expanded Reach After Stelo's US Launch
ZACKS· 2024-08-28 01:01
DexCom Inc. (DXCM) recently announced the availability of Stelo, the first over-the-counter (OTC) continuous glucose monitoring (CGM) biosensor in the United States. The biosensor is available for purchase without a prescription at Stelo.com.Dexcom glucose biosensors are a vital and effective tool for managing diabetes as they produce good clinical results independent of medication use and may even be able to slow down the disease's progression. Glucose biosensors, such as Stelo, can increase the efficacy o ...
Investors in DexCom, Inc. Should Contact The Gross Law Firm Before October 21, 2024 to Discuss Your Rights – DXCM
GlobeNewswire News Room· 2024-08-28 00:55
NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form/?id=98153&from=3 CLASS PERIOD: January 8, 2024 to Jul ...
Levi & Korsinsky Reminds DexCom, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 21, 2024 - DXCM
Prnewswire· 2024-08-27 17:45
NEW YORK, Aug. 27, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DexCom investors who were adversely affected by alleged securities fraud between January 8, 2024 and July 25, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/dexcom-inc-lawsuit-submission-form?prid=9 ...
DXCM Class Action Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the DexCom Inc. Class Action
GlobeNewswire News Room· 2024-08-27 06:55
SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired DexCom Inc. (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024. DexCom is an international company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 3 ...
Dexcom launches first over-the-counter continuous glucose monitor. Here's what it's like
CNBC· 2024-08-26 20:00
In this articleABTDXCMUser wearing Stelo CGM from Dexcom.Courtesy of DexcomDexcom on Monday announced its new over-the-counter continuous glucose monitor Stelo is officially available for purchase in the U.S.Glucose is a type of sugar people receive from food, and it's the body's main source of energy. Continuous glucose monitors, or CGMs, are small sensors that poke through the skin to measure glucose levels in real time. They are typically prescribed to patients with diabetes since they can help alert use ...
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against DexCom, Inc. - DXCM
Prnewswire· 2024-08-23 07:00
NEW YORK, Aug. 22, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether DexCom and certain of its officers and/or d ...
DEXCOM, INC. (NASDAQ: DXCM) INVESTOR ALERT: Investors With Losses in DexCom, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
GlobeNewswire News Room· 2024-08-23 00:47
NEW YORK, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024, inclusive (the “Class Period”). For more information, submit a form at DexCom, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, o ...
SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf DexCom, Inc. (DXCM) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
GlobeNewswire News Room· 2024-08-22 23:27
ATLANTA, Aug. 22, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against DexCom, Inc. (“DexCom” or “the Company”) (NASDAQ: DXCM). The lawsuit alleges that Defendants created the false impression that they possessed reliable information pertaining to the Company’s projected revenue outlook and anticipated growth while also minimizing risk from seasonality and macroeconomic fluctuations. Such statements are alleged to have caused Plaintiff and other shareholders to purchase DexCom’ ...